Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.340
+0.160 (13.56%)
Jul 24, 2025, 4:00 PM - Market closed
Pyxis Oncology Employees
Pyxis Oncology had 44 employees as of December 31, 2024. The number of employees decreased by 6 or -12.00% compared to the previous year.
Employees
44
Change (1Y)
-6
Growth (1Y)
-12.00%
Revenue / Employee
n/a
Profits / Employee
-$2,164,386
Market Cap
83.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Dec 31, 2021 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PYXS News
- 24 days ago - Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Pyxis Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - GlobeNewsWire
- 4 months ago - Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewsWire
- 4 months ago - Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - GlobeNewsWire
- 4 months ago - Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - GlobeNewsWire